Roche says its new in­ter­im up­date on he­mo­phil­ia A drug is pos­i­tive. But it’s hard to gauge.

Roche to­day sent out a small, blur­ry snap­shot of the in­ter­im da­ta from a Phase III study of emi­cizum­ab in chil­dren suf­fer­ing from he­mo­phil­ia A.

What did we find out?

The da­ta are pos­i­tive and “clin­i­cal­ly mean­ing­ful” — though pre­sum­ably not sta­tis­ti­cal­ly sig­nif­i­cant, which is the phrase you look for in de­ter­min­ing suc­cess or fail­ure — in cut­ting the bleed rate among chil­dren 12 or younger with in­hibitors to Fac­tor VI­II.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.